CONTACT US
Share: Share on Facebook Share on Twitter Share on LinkedIn I recommend visiting cushmanwakefield.com to read:%0A%0A {0} %0A%0A {1}
Life Sciences Golden Triangle Report Life Sciences Golden Triangle Report

Life Sciences: Golden Triangle Lab Report

Jamie Renison • 02/05/2024
Our latest Life Sciences Lab Report on the UK's Golden Triangle. The report External Link looks closely at investment volumes, leasing take up, lab supply and pipeline, and investment into life sciences real estate across Cambridge, Oxford and London. 
 

Q2 2024 Take-Up Statistics

  • Golden Triangle leasing activity totalled 39,700 sq ft in Q2 2024.
  • This lull is typical for the second quarter, with 2024 likely to be the fourth year out of the past six where Q2 has reported the lowest quarterly volume of the year.
  • Under-offer space totalled 131,500 sq ft at the close of Q2, including several requirements in excess of 25,000 sq ft, indicating that activity is likely to rebound in Q3.
  • Additionally, active demand requirements ticked up in the quarter, including several major new requirements in excess of 50,000 sq ft.

Evolving Demand and Supply

  • Construction completions for the quarter totalled 53,800 sq ft across the Golden Triangle life sciences market, with two schemes being delivered.
  • At the close of the quarter, 3.6 million sq ft of space was under construction across the Golden Triangle. Of this, 13% has been pre-let, leaving a speculative under-construction pipeline of 3.1 million sq ft.
  • While vacancy remains very low in Cambridge at 1.3%, Oxford and London report higher levels of availability. In the medium term, this additional supply is likely to enable further growth in the sector – a welcome change from the occupier perspective.
  • Prime headline quoting rents in Q2 2024 remained level in all markets with Cambridge at £70.00 psf, Oxford at £62.50 and London at £130.00.

Venture Capital

  • New Venture Capital (VC) funding into UK life sciences companies totalled £684.0 million in Q2 2024, in line with the five-year quarterly average.
  • The Rest of the UK reported the largest share of activity at 33%, equating to £219.3 million – the second highest figure on record for the RoUK market.
  • The M&A market slowed down in Q2 following a bustling first quarter, with only a few global M&A deals and IPOs recorded.

Investment Market Insights

  • For the first half of 2024, the Golden Triangle life sciences real estate investment market saw a continuation of the subdued volumes of investment of 2023.
  • Four transactions, totalling £94.3 million, completed in Q2, which represents a reduction from the long-term quarterly average.
  • Looking ahead, there are a number of major transactions currently being marketed which, once transacted, should result in higher volumes later in the year.
  • Prime yields in the Golden Triangle remained flat over the quarter, at 5.00%.
  • Provided inflation continues to move into line with target, moderate interest rate cuts are expected in H2 2024. In due course this should assist investor appetite.

Read more in our latest quarterly report External Link or get in touch with a member of the team to discuss further.

Resources

Locating science
Research

Locating Science

Assessing the Life Sciences landscape across the UK
10/05/2024
life sciences
Research

Life Sciences Update

The life sciences industry enters 2024 with measured optimism, signaling that the sector has reverted to its long-term trend for growth. A flurry of recent announcements, from strong initial public offerings to exciting new mergers and acquisitions, has breathed new life into the industry.
Sandy Romero • 06/03/2024
istockphoto-idea
GSK Completes Sale Of Strategic Life Sciences Development Site

Real estate services firm Cushman & Wakefield has advised GSK plc on the sale of the surplus development land that sits alongside its 1 million sq ft Research & Development (R&D) facility in Stevenage to UBS Asset Management and Reef Group. 

11/11/2022

Ready to talk?

Get in touch with one of our professionals.
With your permission we and our partners would like to use cookies in order to access and record information and process personal data, such as unique identifiers and standard information sent by a device to ensure our website performs as expected, to develop and improve our products, and for advertising and insight purposes.

Alternatively click on More Options and select your preferences before providing or refusing consent. Some processing of your personal data may not require your consent, but you have a right to object to such processing.

You can change your preferences at any time by returning to this site or clicking on Cookies.
MORE OPTIONS
Agree and Close
These cookies ensure that our website performs as expected,for example website traffic load is balanced across our servers to prevent our website from crashing during particularly high usage.
These cookies allow our website to remember choices you make (such as your user name, language or the region you are in) and provide enhanced features. These cookies do not gather any information about you that could be used for advertising or remember where you have been on the internet.
These cookies allow us to work with our marketing partners to understand which ads or links you have clicked on before arriving on our website or to help us make our advertising more relevant to you.
Agree All
Reject All
SAVE SETTINGS